The global ipilimumab market is poised for robust growth, driven by the escalating burden of cancer and advancements in immunotherapy treatments. Data Bridge Market Research analyses that the ipilimumab? market was valued at USD 2.026 million in 2021 and is expected to reach USD 4.34 million by 2029, registering a CAGR of 10.0% during the forecast period of 2022 to 2029.  Detailed...